International Journal of Hematology

DOI: 10.1007/s12185-013-1303-2 Pages: 465-471

Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL)

1. Uppsala University, Department of Radiology, Oncology, and Radiation Sciences

2. Uppsala University, Department of Immunology, Genetics and Pathology

3. Uppsala University, Rudbeck Laboratory, Departments of Oncology, Radiology and Clinical Immunology

Correspondence to:
Gustav Hedström
Tel: +46-1-86110202
Fax: +46-1-84713432
Email: gustaf.hedstrom@onkologi.uu.se

Close

Abstract

Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of B cell lymphomas. MicroRNA expression provides a new and interesting tool for understanding the biology and clinical course of DLBCL. The present study presents microRNA-129-5p expression data from DLBCL patients treated with CHOP or R-CHOP. Patients with low microRNA-129-5p expression had a median survival of 23 months and a significantly shorter overall survival (P = 0.0042) compared to patients with high microRNA-129-5p expression, who had a median survival of 58 months. We also found that patients treated with R-CHOP only and displaying low microRNA-129-5p expression had a significantly shorter overall survival compared to patients with high microRNA-129-5p expression; all such patients were still alive at the time of last follow-up (P = 0.043). No significant difference was found among microRNA-129-5p expression in tumor tissue, the tissue surrounding the tumor, and normal controls. To our knowledge, this is the first report to show that the expression of microRNA-129-5p can affect the clinical outcome of DLBCL patients and that microRNA-129-5p may be involved in the biology of DLBCL development, although larger studies are necessary to confirm this. Further investigations may also help to elucidate the biological role of microRNA-129-5p in DLBCL.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge